Satsuma Pharmaceuticals (NASDAQ:STSA) Posts Earnings Results, Misses Estimates By $1.25 EPS

Satsuma Pharmaceuticals (NASDAQ:STSA) posted its quarterly earnings data on Tuesday. The financial services provider reported ($2.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($1.25), Fidelity Earnings reports.

NASDAQ:STSA traded up $0.04 during trading hours on Friday, hitting $17.98. 2,305 shares of the stock traded hands, compared to its average volume of 41,760. Satsuma Pharmaceuticals has a 1 year low of $8.61 and a 1 year high of $19.90. The firm has a 50 day moving average of $12.48.

In other news, major shareholder Group Holdings (Sbs) Advis Tpg purchased 100,000 shares of the stock in a transaction on Tuesday, September 17th. The shares were acquired at an average price of $15.00 per share, with a total value of $1,500,000.00. Also, Director Rajeev M. Shah purchased 1,333,333 shares of the stock in a transaction on Tuesday, September 17th. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $19,999,995.00. Insiders have acquired 1,434,333 shares of company stock worth $21,503,805 in the last ninety days. Insiders own 45.65% of the company’s stock.

STSA has been the topic of several analyst reports. Credit Suisse Group initiated coverage on shares of Satsuma Pharmaceuticals in a report on Tuesday, October 8th. They set an “outperform” rating and a $16.00 price target on the stock. Svb Leerink initiated coverage on shares of Satsuma Pharmaceuticals in a report on Tuesday, October 8th. They set an “outperform” rating on the stock. Finally, Leerink Swann initiated coverage on shares of Satsuma Pharmaceuticals in a report on Tuesday, October 8th. They set an “outperform” rating and a $20.00 price target on the stock.

About Satsuma Pharmaceuticals

Satsuma Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled single-use nasal delivery device.

Recommended Story: What are the benefits of investing in REITs?

Earnings History for Satsuma Pharmaceuticals (NASDAQ:STSA)

Receive News & Ratings for Satsuma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Satsuma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.